Plexus saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 69 to 75.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique rating identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if Plexus can continue to rebound and clear that threshold.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to form a base and break out.
Earnings growth fell in the most recent report from 41% to 39%. But revenue moved higher, from -1% to 1%.
Plexus earns the No. 7 rank among its peers in the Electronics-Contract Manufacturing industry group. Celestica, TTM Technologies and Fabrinet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
